Live from IMS 2026: EXCALIBER-RRMM: First Phase 3 CELMoD Data With MRD-Negative CR as a Dual Primary Endpoint in RRMM

Sep 22, 2026 | Multiple Myeloma

2) This program, intended for #HCPs, is supported by an independent educational grant from Bristol Myers Squibb. Follow this 🧵for 🆓1.0h CE/#CME! Statement of accreditation & faculty disclosures at https://t.co/8oShcATWla. FOLLOW US for expert-led #MedEd in...

LIVE from ASCO26: New Data on CELMoD Therapy for Multiple Myeloma

May 31, 2026 | Multiple Myeloma

2) This program, intended for #HCPs, is supported by an independent educational grant from Bristol Myers Squibb. Follow this 🧵for 🆓1.0h CE/#CME! Statement of accreditation & faculty disclosures at https://t.co/8oShcATovC. FOLLOW US for expert-led #MedEd in...